<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025545</url>
  </required_header>
  <id_info>
    <org_study_id>1099.00</org_study_id>
    <secondary_id>FHCRC-1099.00</secondary_id>
    <secondary_id>NCI-H01-0078</secondary_id>
    <secondary_id>CDR0000068972</secondary_id>
    <nct_id>NCT00025545</nct_id>
  </id_info>
  <brief_title>Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia&lt;/p&gt;</brief_title>
  <official_title>A Phase II Trial to Evaluate the Use of G-CSF-Mobilized Peripheral Blood Progenitor Cells as Hematopoietic Rescue in Patients With Acute Leukemia Undergoing Allografting From an Unrelated Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's
      tissues. Treating donor peripheral stem cells with filgrastim may increase the number of
      donor white blood cells. This may help to decrease the rejection of the transplanted cells in
      patients receiving them as treatment for acute leukemia.

      PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral
      stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell
           transplantation reduces the incidence of non-leukemic mortality in patients with acute
           leukemia.

        -  Determine the kinetics and durability of engraftment after treatment with this regimen
           in these patients.

        -  Determine the incidence and severity of acute and chronic graft-versus-host disease in
           patients treated with this regimen.

        -  Determine the leukemia-free survival of patients treated with this regimen.

      OUTLINE: Donors receive filgrastim (G-CSF) subcutaneously (SC) on days -5 to -1. Donors then
      undergo leukapheresis on days -1 and 0.

      Patients undergo total body irradiation twice daily on days -7 to -4. Patients receive 2
      doses of intrathecal methotrexate per local guidelines between days -10 and -3. Patients also
      receive cyclophosphamide IV on days -3 and -2. Patients receive infusion of allogeneic
      peripheral blood stem cells on day 0.

      PROJECTED ACCRUAL: A total of 5-60 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  One of the following diagnoses:

               -  Primary acute leukemia beyond first remission

               -  High-risk acute myelogenous leukemia

               -  Acute lymphoblastic leukemia in first remission

          -  Must have HLA-matched donor identical for HLA-A, -B, and DRB1 alleles

               -  No HLA-matched identical sibling or haploidentical relative incompatible for 0 or
                  1 HLA-A, -B, or -DRB1 loci on the non-shared haplotype

          -  No leukoencephalopathy

        PATIENT CHARACTERISTICS:

        Age:

          -  55 and under

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  SGOT no greater than 2 times normal

          -  Hepatitis B surface antigen negative

          -  No prior hepatitis C

        Renal:

          -  No impaired renal function

          -  Creatinine less than 2 times normal

        Cardiovascular:

          -  No symptomatic cardiac disease

        Pulmonary:

          -  No active pulmonary disease

          -  DLCO at least 60% predicted

        Other:

          -  HIV negative

          -  No disease or other malignancy that severely limits life expectancy

          -  No severe or life-threatening infection within the past 2 weeks

          -  No history of septate fungal infection or disseminated candidiasis

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior bone marrow or peripheral blood stem cell transplantation

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy greater than 3,000 cGy to whole brain

          -  No prior radiotherapy of 1,500 cGy to chest or abdomen

          -  At least 6 months since prior involved-field radiotherapy to chest or abdomen

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Anasetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>June 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2003</study_first_posted>
  <last_update_submitted>May 12, 2010</last_update_submitted>
  <last_update_submitted_qc>May 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2010</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

